Qilu always commits itself to offering high-quality & trustworthy medicines to the world and improving people’s well-being. It is the first Chinese company to obtain both USFDA and EDQM approval for sterile APIs. Its Finished Formulations and APIs have been approved by USFDA, EMA, TGA, MHRA, PMDA, etc. Qilu maintains a robust and sustainable growth in global markets while consistently foraying into new geographies to further fortify its position globally. With a well-established domestic and overseas sales network, you may find Qilu’s footprints across the world.
Year Established: 1958
Total Number of Staff: more than 1000
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Business Type: All
R&D Capacity: Own Brand
Main Sales Markets : North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Subscribe to the latest newsletter of Virtual Expo Connect